Biomedical researchers at Sanford Burnham Prebys have found that increasing levels of a natural brain protein called SORLA protects against toxic tau tangles, a primary driver of Alzheimer's disease and dementia.
The study, published in Science Advances on July 17, 2026, shows that elevated SORLA suppresses neurodegeneration by halting hyperphosphorylation and preventing abnormal tau proteins from spreading across neural networks.
This reduces brain shrinkage and preserves vital synaptic connections.
While SORLA was previously known to prevent amyloid-beta accumulation, its protective role against tau-driven damage had remained largely unknown.
To analyze its effects, scientists crossbred genetically engineered mice possessing human SORLA with models displaying tau tangles and cognitive deficits.
"In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer's disease -- amyloid-beta generation and accumulation," said Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys.
The research demonstrated that elevated protein levels effectively shielded communication junctions between neurons and reduced brain tissue loss.
"Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer's disease," said Tim Huang.
The findings indicated that boosting the protein led directly to measurable neuroprotective benefits in animal models.
"When you upregulate SORLA, you can suppress the negative effects found in tauopathies," said Huijie Huang, PhD, a staff scientist in the Huang lab at Sanford Burnham Prebys and lead author of the study.
Researchers observed substantial physical improvements in the brain structures of the tested subjects.
"We found there was less brain atrophy and less tau accumulation, which was very exciting to see," said Huijie Huang.
In contrast, when scientists examined mice genetically altered to lack the Sorl1 gene responsible for producing SORLA, cellular damage and neurodegeneration accelerated significantly.
"The opposite turned out to be true when we deleted the ability to produce SORLA proteins," said Tim Huang, senior and corresponding author of the manuscript.
The absence of the protective protein intensified overall cognitive and structural degradation.
"A lack of SORLA exacerbated the harmful effects observed in tauopathies," said Tim Huang.
Advanced cellular sequencing further showed that a lack of SORLA triggered the overactivation of specific receptor pathways in glial cells, which maintain the neuronal environment.
"One particularly notable finding that we can build on is the upregulation of a member of the plexin-B family of receptors in the absence of SORLA," said Huijie Huang.
This discovery highlights potential targets for existing pharmaceutical compounds.
"There are unique drugs that can target this class of receptors that we may be able to apply to tau-related dementia disorders," said Tim Huang.
Modulating these biological pathways could eventually offer remedies for cellular inflammation.
"One potential future direction is to repurpose these drugs to target overactivation of glial cells and perhaps reverse some of the phenotypes in tauopathies," said Tim Huang.
To build upon these findings, scientists plan to graft human cells into animal models to observe SORLA mutations within living human neural environments.
"Mouse cells and human cells are different," said Tim Huang.
Future clinical translation relies on observing these mechanism dynamics directly within human tissue contexts.
"Because we're looking at human disease, it's more informative if we can observe the modulation and dysfunction of SORLA in the context of a human cell inside of a diseased brain environment," said Tim Huang.
Parallel research also highlights how toxic tau spreads between neurons using tiny biological bubbles called extracellular vesicles associated with the Arc protein.
While Arc aids in cellular clearance, intercepting these vesicles after release offers another prospective pathway for limiting disease progression alongside SORLA-targeted therapies.
